Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis.


Journal

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN: 1534-4436
Titre abrégé: Ann Allergy Asthma Immunol
Pays: United States
ID NLM: 9503580

Informations de publication

Date de publication:
03 2022
Historique:
received: 07 07 2021
revised: 27 08 2021
accepted: 06 10 2021
pubmed: 13 10 2021
medline: 17 3 2022
entrez: 12 10 2021
Statut: ppublish

Résumé

Patients with systemic mastocytosis (SM) are at increased risk of hypersensitivity reactions (HRs). Although Hymenoptera venoms are the predominant triggers, cases of contrast media-induced HR (CMIHR) have also been reported and prophylactic premedication is often performed. However, data from larger series are limited and differences between indolent and advanced SM have not yet been investigated. To determine the incidence and severity of CMIHR in all subtypes of SM. We analyzed 162 adult patients with SM (indolent systemic mastocytosis [ISM], n = 65; advanced systemic mastocytosis [advSM], n = 97). First, the cumulative incidence of CMIHR was retrospectively assessed in the patient's history. Second, at our institution, patients underwent 332 contrast media (CM)-enhanced imaging including 80 computed tomography (CT) scans with iodine-based contrast agent and 252 magnetic resonance imaging (MRI) with a gadolinium-based contrast agent, and tolerance was assessed. Previous CMIHRs to CT (vomiting, n = 1, erythema, n = 1, cardiovascular shock, n = 1), and MRI (dyspnea, n = 1, cardiovascular shock, n = 1) had been reported by 4 out of 162 (2.5%) patients (ISM, n = 3; advSM, n = 1). In contrast, during or after 332 CM-enhanced CT or MRI examinations at our institution, no CMIHRs were reported. Premedication was solely given to 3 patients before CT scans, including 1 with previous CMIHR, who tolerated the imaging well. We conclude that: (1) there is a substantial discrepancy between the perception and prevalence of HRs to CM in SM; (2) reactions are scarce in ISM and even rarer in advSM; and (3) in SM patients without previous history of CM hypersensitivity, prophylactic premedication before CM-enhanced CT or MRI is dispensable.

Sections du résumé

BACKGROUND
Patients with systemic mastocytosis (SM) are at increased risk of hypersensitivity reactions (HRs). Although Hymenoptera venoms are the predominant triggers, cases of contrast media-induced HR (CMIHR) have also been reported and prophylactic premedication is often performed. However, data from larger series are limited and differences between indolent and advanced SM have not yet been investigated.
OBJECTIVE
To determine the incidence and severity of CMIHR in all subtypes of SM.
METHODS
We analyzed 162 adult patients with SM (indolent systemic mastocytosis [ISM], n = 65; advanced systemic mastocytosis [advSM], n = 97). First, the cumulative incidence of CMIHR was retrospectively assessed in the patient's history. Second, at our institution, patients underwent 332 contrast media (CM)-enhanced imaging including 80 computed tomography (CT) scans with iodine-based contrast agent and 252 magnetic resonance imaging (MRI) with a gadolinium-based contrast agent, and tolerance was assessed.
RESULTS
Previous CMIHRs to CT (vomiting, n = 1, erythema, n = 1, cardiovascular shock, n = 1), and MRI (dyspnea, n = 1, cardiovascular shock, n = 1) had been reported by 4 out of 162 (2.5%) patients (ISM, n = 3; advSM, n = 1). In contrast, during or after 332 CM-enhanced CT or MRI examinations at our institution, no CMIHRs were reported. Premedication was solely given to 3 patients before CT scans, including 1 with previous CMIHR, who tolerated the imaging well.
CONCLUSION
We conclude that: (1) there is a substantial discrepancy between the perception and prevalence of HRs to CM in SM; (2) reactions are scarce in ISM and even rarer in advSM; and (3) in SM patients without previous history of CM hypersensitivity, prophylactic premedication before CM-enhanced CT or MRI is dispensable.

Identifiants

pubmed: 34637924
pii: S1081-1206(21)01134-0
doi: 10.1016/j.anai.2021.10.004
pii:
doi:

Substances chimiques

Arthropod Venoms 0
Contrast Media 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

314-318

Informations de copyright

Copyright © 2021 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Juliana Schwaab (J)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Knut Brockow (K)

Faculty of Medicine, Department of Dermatology and Allergology Biederstein, Technical University of Munich, School of Medicine, Munich, Germany.

Philipp Riffel (P)

Clinic of Clinical Radiology and Nuclear Medicine, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.

Johannes Lübke (J)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Nicole Naumann (N)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Mohamad Jawhar (M)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Lukas Reiter (L)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Alice Fabarius (A)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Georgia Metzgeroth (G)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Stefan O Schoenberg (SO)

Clinic of Clinical Radiology and Nuclear Medicine, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.

Wolf-Karsten Hofmann (WK)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Andreas Reiter (A)

Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Julia Riffel (J)

Clinic of Clinical Radiology and Nuclear Medicine, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: julia.riffel@medma.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH